Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL106104 | 0.77 | ALDH1A1 (0.39) | ALDH1A1HDAC4 | |
| SCHEMBL20587670 | 0.75 | ALDH1A1 (0.59) | ALDH1A1CES2CES1 | |
| SCHEMBL68148 | 0.75 | ALDH1A1 (0.59) | ALDH1A1CES2CES1 | |
| SCHEMBL10730175 | 0.75 | SRD5A2 (0.38) | ALDH1A1HDAC4HSD11B1 | |
| SCHEMBL9472249 | 0.75 | ESR1 (0.55) | ALDH1A1HDAC4RXRAHSD11B1 | |
| SCHEMBL29119934 | 0.74 | ALDH1A1 (0.41) | ALDH1A1HDAC4CCR2RXRA | |
| SCHEMBL21882888 | 0.74 | PRKAB2 (0.41) | ALDH1A1HSD11B1 | |
| Cyclohexane SCHEMBL28345268 | 0.73 | ALDH1A1 (0.52) | ALDH1A1CES2CES1 | |
| SCHEMBL6758498 | 0.72 | ALDH1A1 (0.64) | ALDH1A1CES2CES1 | |
| Ammonia Solution, Strong SCHEMBL2023211 | 0.72 | ALDH1A1 (0.56) | ALDH1A1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205564-B1 | NOVEL KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-07-30 | — | — | EP | disclosed |
| EP-2426109-B1 | NOVEL KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-18 | — | — | EP | disclosed |
| EP-2426109-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-07 | — | — | EP | disclosed |
| US-7943618-B2 | Btk protein kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-05-17 | — | — | US | disclosed |
| CN-101835755-A | Novel kinase inhibitors | HOFFMANN LA ROCHE | 2010-09-15 | — | — | CN | disclosed |
| EP-2205564-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009053269-A1 | NOVEL KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | ALDH1A1 3990/4885HDAC4 3397/4885CCR2 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.